


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:






LISTING OF CLAIMS:

1. **(currently amended):** A prostaglandin derivative represented by Formula (I):



wherein X is a halogen atom in the α - or β -position, Y is an ethylene group, a vinylene group or an ethynylene group,

A is a group represented by the formula:



(wherein n is an integer of 1 to 5, p is 0, 1 or 2, q is an integer of 1 to 3, and r is 0 or 1),

R^1 is a C_{3-10} cycloalkyl group, a C_{1-4} alkyl- C_{3-10} cycloalkyl group, a C_{3-10} cycloalkyl- C_{1-4} alkyl group, a C_{5-10} alkyl group, a C_{5-10} alkenyl group, a C_{5-10} alkynyl group or a bridged cyclic hydrocarbon group,

R^2 is a hydrogen atom, a C_{1-10} alkyl group or a C_{3-10} cycloalkyl group, and

m is 0, 1 or 2}, a pharmaceutically acceptable salt thereof or a hydrate thereof.




2. (original): The prostaglandin derivative of Formula (I) according to Claim 1 wherein R^1 is a C_{3-10} cycloalkyl group, a C_{1-4} alkyl- C_{3-10} cycloalkyl group, a C_{3-10} cycloalkyl- C_{1-4} alkyl group, a branched C_{5-10} alkyl group, a branched C_{5-10} alkenyl group, a branched C_{5-10} alkynyl group or a bridged cyclic hydrocarbon group; the pharmaceutically acceptable salt thereof or the hydrate thereof.

3. (original): The prostaglandin derivative of Formula (I) according to Claim 2 wherein X is a chlorine or bromine atom in the α - or β -position, R^1 is a C_{3-10} cycloalkyl group, a C_{3-10} cycloalkyl- C_{1-4} alkyl group or a branched C_{5-10} alkenyl group, and R^2 is a hydrogen atom or a C_{1-10} alkyl group; the pharmaceutically acceptable salt thereof or the hydrate thereof.

4. (currently amended): The prostaglandin derivative of Formula (I) according to ~~any one of Claims 1 to 3~~ wherein Y is a vinylene group; the pharmaceutically acceptable salt thereof or the hydrate thereof.

5. (currently amended): The prostaglandin derivative of Formula (I) according to ~~any one of Claims 1 to 3~~ wherein Y is an ethynylene group; the pharmaceutically acceptable salt thereof or the hydrate thereof.

6. (currently amended): The prostaglandin derivative of Formula (I) according to ~~any one of Claims 1 to 5~~ wherein A is a group represented by the formula:



(wherein n is an integer of 1 to 5, p is 0, 1 or 2, q is an integer of 1 to 3, and r is 0 or 1);
the pharmaceutically acceptable salt thereof or the hydrate thereof.

7. (original): The prostaglandin derivative of Formula (I) according to Claim 6 wherein p is 0; the pharmaceutically acceptable salt thereof or the hydrate thereof.

8. (original): A pharmaceutical preparation which comprises as an effective ingredient the prostaglandin derivative according to any one of Claims 1 to 7, the pharmaceutically acceptable salt thereof or the hydrate thereof.